CLINICAL TRIALS PROFILE FOR CIALIS
✉ Email this page to a colleague
All Clinical Trials for Cialis
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00050609 ↗ | Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying | Completed | ICOS Corporation | Phase 2 | 2003-02-01 | The purposes of this study are to determine whether an experimental drug known as tadalafil can reduce symptoms of dyspepsia (fullness after eating, inability to finish a regular meal, bloating, discomfort or pain in the upper abdomen, belching after meals, nausea, vomiting) in diabetic patients, and/or reduce the amount of time the stomach takes to empty the contents of a standard meal. The safety of tadalafil given once daily for 8 weeks in this population will also be studied. |
| NCT00050609 ↗ | Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying | Completed | Eli Lilly and Company | Phase 2 | 2003-02-01 | The purposes of this study are to determine whether an experimental drug known as tadalafil can reduce symptoms of dyspepsia (fullness after eating, inability to finish a regular meal, bloating, discomfort or pain in the upper abdomen, belching after meals, nausea, vomiting) in diabetic patients, and/or reduce the amount of time the stomach takes to empty the contents of a standard meal. The safety of tadalafil given once daily for 8 weeks in this population will also be studied. |
| NCT00125918 ↗ | PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension | Completed | ICOS Corporation | Phase 3 | 2005-08-01 | The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the treatment of pulmonary arterial hypertension. |
| NCT00125918 ↗ | PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension | Completed | Eli Lilly and Company | Phase 3 | 2005-08-01 | The purpose of this study is to evaluate the safety and effectiveness of tadalafil for the treatment of pulmonary arterial hypertension. |
| NCT00174486 ↗ | Assessment Of Duration Of Action, Safety & Toleration Of UK369,003 and Cialis In Patients With Erectile Dysfunction | Completed | Pfizer | Phase 2 | 2005-02-01 | Assessment of duration of action, safety & toleration of different formulations and doses of UK-369,003 and Cialis in patients with male erectile dysfunction. Patients should have previously been on PDE5 inhibitors and have been respondents to the drug. Duration of treatment is 4 weeks. |
| NCT00215631 ↗ | Can Tadalafil Maintain Erectile Function In Patients Treated With Radiotherapy For Prostate Cancer? | Terminated | Erasmus Medical Center | Phase 3 | 2005-10-01 | Because of the high incidence of post-radiation erectile dysfunction (ED), up to 72% after external-beam radiotherapy, this patient category represents a most difficult therapeutic challenge. Therefore, prevention of ED could be more effective than treatment. Tadalafil, a new phosphodiesterase type 5 inhibitor, has been recently introduced. No studies have investigated the efficacy of tadalafil in preventing ED in patients undergoing radiotherapy for prostate cancer. Efficacy of tadalafil can last up to 36 hours after intake. This will result in a prolonged and continuos enhancement of penile vascular responsiveness. This randomized, double-blind, placebo-controlled study has been designed to evaluate the efficacy of 20-mg of tadalafil administered for 12 months in maintaining erectile function of potent patients undergoing external-beam radiotherapy for prostate cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cialis
Condition Name
Clinical Trial Locations for Cialis
Trials by Country
Clinical Trial Progress for Cialis
Clinical Trial Phase
Clinical Trial Sponsors for Cialis
Sponsor Name
